OBR Radar
Stay ahead of market moving oncology events and peer into the future of the oncology industry with the new OBR Radar.





Latest Pharmacology/Biotech News Headlines

OBR daily Pharmacology/Biotech E-news archives»

Insurers Propose Universal, Centralized Healthcare

(Los Angeles Times) Dec 4, 2008 - Several consumer groups criticize the early bid by America's Health Insurance Plans, a trade group that fought an overhaul in the 1990s, to take an active role in Obama's effort to revamp the system.
read article (free registration required) 



More Job Cuts at Sanofi, This Time in the US

(Wall Street Journal Health Blog) Dec 3, 2008 - Chris Viehbacher, the new CEO of Sanofi-Aventis, isn’t a man to let the grass grow under his feet. Just two days in his new job, and Sanofi is cutting its U.S. sales force, Dow Jones Newswires reports.
read article (paid subscription required) 



New Website to Help Hospitals Deal With CMS Recovery Audit Contractors

(StreetInsider.com) Dec 4, 2008 - An Internet portal designed to provide hospitals and health systems with a single source for the latest news and information, on The Centers for Medicare & Medicaid Services (CMS) Recovery Auditor Contractor (RAC) program, is rolling out this week at www.racmonitor.com.
read article 



FDA Asks Roche For More Data On Key Drug Actemra

(CNNMoney.com) Dec 4, 2008 - Roche Holding AG suffered a severe setback Thursday for its most promising new drug, Actemra, when the U.S. Food and Drug Administration asked for a new animal trial and other information, which will delay its launch by at least 18 months.
read article 



Novartis Malaria Drug Is Safe, Effective, FDA Says

(Wall Street Journal) Dec 3, 2008 - A Food and Drug Administration panel said clinical studies showed a Novartis AG malaria drug was safe and effective at treating one type of the mosquito-borne illness.
read article (paid subscription required) 



An Insurer Gives Lipitor Users a Break

(The Star-Ledger) Dec 4, 2008 - Health insurer Cigna has reduced consumers' co-payments for the world's top-selling drug, the cholesterol fighter Lipitor, saying it will help keep the medicine affordable during the economic slump.
read article